Iron Deficiency Injectables Market

Global Iron Deficiency Injectables Market:

The global iron deficiency injectables market size reached US$ 13.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 36.9 Billion by 2032, exhibiting a growth rate (CAGR) of 11.78% during 2024-2032. The growing geriatric population, along with the increasing prevalence of chronic diseases, is bolstering the market.

Iron Deficiency Injectables Market Analysis:

• Major Market Drivers: The growing prevalence of anemia worldwide is boosting the need for quick and effective treatments, which is accelerating the market.
• Key Market Trends: Improved healthcare access in developing regions is expanding the use of injectable iron therapies, thereby acting as a significant growth-inducing factor.
• Competitive Landscape: Some of the major market companies include AbbVie Inc., BSA Pharma Inc., Covis Pharma GmbH, CSL Vifor (CSL Limited), Daiichi Sankyo Company Limited, Pharmacosmos A/S, Sandoz AG, Sanofi S.A., and Systacare Remedies., among many others.
• Geographical Trends: North America and Europe see strong adoption of injectables due to advanced healthcare. Moreover, Asia Pacific is experiencing growth from increasing anemia cases. Apart from this, the rising demand for improving healthcare access is augmenting the market across Latin America and the Middle East and Africa.
• Challenges and Opportunities: The high risk of side effects is hindering the market. However, improving formulation safety and patient monitoring techniques will continue to catalyze the market over the forecasted period.
   

Iron Deficiency Injectables Market Trends:

Rising Awareness of Anemia Treatments

The growing public health campaigns and medical advancements have increased awareness about the importance of early diagnosis and treatment for anemia. Furthermore, this heightened attention is leading to more frequent use of injectable iron therapies, particularly for patients who struggle with oral iron options. For instance, in March 2024, Cadila Pharmaceuticals launched a new iron injection aimed at addressing anemia and providing an exemplary safety profile. This aims to meet the growing demand for effective treatments for iron deficiency.

Increasing Innovations in Iron Injectables

Continuous research and development are improving the safety, efficacy, and convenience of iron injectables. In contrast, these innovations provide more targeted, effective solutions, leading to better outcomes and fewer side effects. Thus, encouraging wider adoption among healthcare providers and patients. For instance, in April 2024, Indian scientists at AIIMS Delhi developed a low-cost, single-dose intravenous iron injection designed for pregnant women. These injectables aim to reduce India's high anemia rates without side effects, thereby improving maternal health under the Anemia Mukt Bharat scheme.

Growing Regulatory Approvals Worldwide

Regulatory agencies in various regions are increasingly approving new iron injectables, which expands treatment options for iron deficiency. Moreover, these approvals reflect the ongoing demand for effective, accessible solutions to treat anemia in different populations, thereby improving patient access to advanced care globally. For instance, in March 2024, Health Canada approved Ferinject (ferric carboxymaltose) for treating iron deficiency anemia in adults and children over one year old, and iron deficiency in heart failure patients. This offers a new option for patients unresponsive to oral iron treatments.

Global Iron Deficiency Injectables Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, indication, branded/generics, and distribution channel.

Breakup by Product Type:

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Others
   

The report has provided a detailed breakup and analysis of the market based on the product type. This includes iron dextran, iron sucrose, ferric carboxymaltose, and others.

Iron deficiency injectables like iron dextran, iron sucrose, and ferric carboxymaltose are used to treat anemia when oral iron is ineffective. Along with this, these formulations differ in dosing frequency and safety profiles, with ferric carboxymaltose offering single-dose convenience and minimal side effects.

Breakup by Indication:

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Others
   

The report has provided a detailed breakup and analysis of the market based on the indication. This includes chronic kidney disease, inflammatory bowel disease, cancer, and others.

Iron deficiency injectables are vital in managing patients with conditions, such as chronic kidney disease, inflammatory bowel disease, cancer, and other type of disease related to iron deficiency. In contrast, these injectables are particularly useful when oral iron treatments fail, thereby helping to effectively replenish iron levels and improve overall patient outcomes in severe deficiency cases.

Breakup by Branded/Generics:

• Branded
• Generics
   

The report has provided a detailed breakup and analysis of the market based on the branded/generics. This includes branded and generics.

Branded iron deficiency injectables are typically marketed at higher prices with patented formulations, while generics version offers more affordable alternatives after patents expire. Furthermore, both address the same condition, though generics aim to expand accessibility, particularly in regions with high anemia prevalence.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
   

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and online pharmacies.

Hospital pharmacies provide iron deficiency injectables for inpatient care, ensuring timely treatment. At the same time, retail pharmacies offer it for patients with prescriptions, thereby supporting outpatient management. Meanwhile, online pharmacies increase accessibility by delivering injectables directly to patients and enhancing convenience, especially for those in remote areas.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
  • Turkey
  • Saudi Arabia
  • Others
     

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa (Turkey, Saudi Arabia, and others).

According to the iron deficiency injectables market report, in Asia Pacific, the growing awareness and rising anemia cases are increasing the demand for iron injectables. In contrast, Europe and North America focus on treating chronic conditions with injectables. Meanwhile, Latin America, the Middle East, and Africa see rising demand due to improved healthcare systems and greater access to treatments. Increased investment in medical facilities and expanded healthcare access are enabling more patients to receive timely treatment for iron deficiency, thereby boosting injectable usage in these regions.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market iron deficiency injectables companies have also been provided. Some of the key players in the market include:

• AbbVie Inc.
• BSA Pharma Inc.
• Covis Pharma GmbH
• CSL Vifor (CSL Limited)
• Daiichi Sankyo Company Limited
• Pharmacosmos A/S
• Sandoz AG
• Sanofi S.A.
• Systacare Remedies
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

 Iron Deficiency Injectables Market Recent Developments:

• April 2024: AIIMS Delhi developed a low-cost, single-dose intravenous iron injection designed for pregnant women to reduce India's high anemia rates without side effects, improving maternal health under the Anaemia Mukt Bharat scheme.
• March 2024: Cadila Pharmaceuticals launched a new iron injection to address anemia. This injectable provides an exemplary safety profile and aims to meet the growing demand for effective treatments for iron deficiency.
• March 2024: Health Canada approved Ferinject (ferric carboxymaltose) for treating iron deficiency anemia in adults and children over one year old and iron deficiency in heart failure patients.

Iron Deficiency Injectables Market Report Scope:

Key Questions Answered in This Report:

• How has the global iron deficiency injectables market performed so far, and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global iron deficiency injectables market?
• What are the key regional markets?
• What is the breakup of the market based on the product type?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the branded/generics?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global iron deficiency injectables market, and who are the key players?
• What is the degree of competition in the industry?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the iron deficiency injectables market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global iron deficiency injectables market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the iron deficiency injectables industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.